Steven Ryder - 14 Feb 2025 Form 4 Insider Report for Rallybio Corp (RLYB)

Reporting relationship: Chief Medical Officer
Issuer ticker: RLYB
Reported as of: 14 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 19:29:06 UTC
Prior SEC filing: 12 Sep 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael Greco, Attorney-in-Fact

Key filing fact

Steven Ryder filed Form 4 for Rallybio Corp (RLYB) on 19 Feb 2025.

Key facts

This page summarizes Steven Ryder's Form 4 filing for Rallybio Corp (RLYB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 19:29.

Change

Previous filing in this sequence was filed on 12 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLYB transaction Derivative

Option (Right to Buy)

Award

Transaction value: $0
Shares: +180,000
Change %
Price: $0.000000
Shares after: 180,000
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 180,000
Exercise price: $0.7600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 14, 2029.